Brain Cancer Companies, Corporate Growth and Development Strategy

Latest Updates of Key Players in the Brain Cancer Market 2026

Roche Holding AG

Headquarters: Switzerland
Latest Updates: Roche prolonged its healthcare research program with novel trials examining personalized treatments for glioblastoma, one of the most aggressive forms of brain cancer.

Novartis AG

Headquarters: Switzerland
Latest Updates: Novartis is reimagining cancer care with RLT for patients with advanced cancers

Pfizer Inc.

Headquarters: United States
Latest Updates: Pfizer is committed to generating a pipeline of novel cancer medicines, treatments, and clinical trials that enhance the outlook for cancer patients globally

Merck & Co., Inc.

Headquarters: United States
Latest Updates: In June 2025, Merck announced the presentation of novel oncology information across more than 12 tumor types at the 2025 American Society of Clinical Oncology (ASCO).

Bristol-Myers Squibb

Headquarters: United States
Latest Updates: Bristol Myers Squibb provides brain cancer resources for patients and caregivers, involving data related to brain tumor management.

AstraZeneca PLC

Headquarters: Finland
Latest Updates: AstraZeneca develops its ambition to redefine haematology care with novel information from its various pipelines.

Value Chain Analysis – Brain Cancer Market

R&D:

• Research and development (R&D) processes in brain cancer treatment includes a inclusive, many-stage pipeline, from drug development and preclinical testing to clinical trials and regulatory processes.
• Key Players: Apollo Hospitals and HCG Hospitals

Management Processes:

• The management of brain cancer includes a complete, multidisciplinary approach that generally includes diagnosis and staging, significant cancer treatments, and ongoing supportive and rehabilitative care.
• Key Players: Max Healthcare and Fortis Hospitals

Patient Services:

• Patient services for brain cancer mix high-precision healthcare treatments with inclusive supportive care to address physical, emotional, and practical risks via the treatment processes.
• Key Players: Merck and Medanta

Market Growth

The global brain cancer market size was estimated at USD 3.09 billion in 2025 and is predicted to increase from USD 3.4 billion in 2026 to approximately USD 8.06 billion by 2035, expanding at a CAGR of 10.07% from 2026 to 2035.

Recent Developments in the Brain Cancer Market

• In December 2025, Curasight A/S announced the successful and safe dosing of the first patient in the Phase 1 trial using uTREAT in brain cancer.
• In October 2025, Northwest Biotherapeutics, Inc., a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, announced that its acquisition of Advent BioServices Ltd. had closed.

Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com